When given passively or elicited actively, antibodies induced by a detoxified Escherichia coli J5 mutant lipopolysaccharide (J5dLPS)-group B meningococcal outer membrane protein (-OMP) vaccine previously protected animals from lethal sepsis. To assess the use of this vaccine for the treatment of Gram-negative bacillary pneumonia, we vaccinated mice, with or without the adjuvant CpG, by intranasal (i.n.) or intraperitoneal (i.p.) routes of administration. Local and systemic IgG levels were 2-3 logs higher following i.p. immunization compared to i.n. However, i.n. immunization elicited both local and systemic IgA, unlike i.p. administration. The addition of CpG to the vaccine, by either route of administration, elicited greater levels of antibody. Intranasal immunization protected mice against lethal heterologous Gram-negative bacillary pneumonia and post-immunization serum and bronchoalveolar lavage fluid mediated enhanced bacterial killing with peritoneal and alveolar macrophages in vitro. We conclude that further studies on the use of J5dLPS-OMP for the prevention of nosocomial pneumonia are warranted.
INTRODUCTION
Gram-negative bacillary infections are commonly associated with high morbidity and mortality, despite appropriate antimicrobial therapy and supportive care. 1 Nosocomial pneumonias, commonly caused by Gramnegative bacillary pathogens, are responsible for up to 50% of deaths from hospital-acquired infections. 2 Effective treatment is becoming limited by the rising emergence of multiple-drug resistant pathogens, 3 making additional strategies for the treatment of these infections increasingly important. Immunotherapy with anti-O and/or K antigen-specific antibodies has been proposed for the treatment of Gram-negative bacillary pathogens, [4] [5] [6] but the diversity of antigenic serotypes among Klebsiella spp., Pseudomonas aeruginosa and Escherichia coli alone makes these serotype-specific antibody approaches too narrow for clinical use. However, the use of an antibody against a conserved antigen can theoretically provide broad, heterologous protection against Gram-negative bacillary infections.
Since the core oligosaccharides of a number of endotoxins (or lipopolysaccharides, LPSs) are conserved, the use of anti-core glycolipid antibodies for the prevention and/or treatment of sepsis has been proposed. [7] [8] [9] [10] An Rc chemotype mutant bacterial strain derived from E. coli O111:B4, designated J5, lacks the O-polysaccharide chain, thereby exposing the core glycolipid region to the immune system. 7 Early studies using passive administration of anti-serum against E. coli J5 showed protection in
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Intranasal administration of a detoxified endotoxin vaccine protects mice against heterologous Gramnegative bacterial pneumonia Wilbur H. Chen 1 , Tae Jin Kang 1 animal models of lethal sepsis 8, 9 as well as in a prospective, randomized, human clinical trial. 10 Subsequently, passive and active administration of antibodies elicited from a subunit vaccine composed of a detoxified E. coli J5 LPS complexed to group B meningococcal outer membrane protein (J5dLPS-OMP) showed protection in animal models of sepsis. 11, 12 The risk of nosocomial pneumonia is dependent on a variety of factors but usually is preceded by the colonization of the respiratory mucosal surface by a pathogenic organism. Therefore, the initial infection might be attenuated or prevented by adequate mucosal immune responses. Parenteral immunization is effective at inducing systemic responses for the prevention of systemic diseases (e.g. hepatitis B virus) but generally does not elicit mucosal immunity. 13 In principle, the most appropriate defense against pneumonia would be a vaccine capable of inducing both systemic and mucosal immunity.
Since nosocomial infections are so pervasive, we wanted to examine the ability of our core glycolipid vaccine to provide protection against Gram-negative bacillary pneumonia. In this study, we assessed the antibody response of J5dLPS-OMP when given by a mucosal (intranasal, i.n.) in comparison to a parenteral (intraperitoneal, i.p.) route of administration. We evaluated the ability of a synthetic unmethylated cytidine-phosphateguanosine (CpG) dinucleotide containing oligodeoxynucleotides (ODNs) to act as an adjuvant for this vaccine. Challenge studies were conducted to determine whether the core glycolipid vaccine would afford protection against lethal pulmonary infection with heterologous Gram-negative bacteria. Antibodies elicited by active vaccination were examined for the ability to promote phagocytosis and killing of bacteria in macrophages as a potential mechanism of action.
MATERIALS AND METHODS

Reagents
The vaccine used in all experiments was the previously characterized J5dLPS-OMP, containing 100 µg/ml of LPS and 136 µg/ml of outer membrane protein by weight. 11 The adjuvant CpG ODN 2006 was obtained from Coley Pharmaceutical Group (Ottawa, Canada). The highly virulent Klebsiella pneumoniae O1:K2 strain was originally obtained from Drs Ida and Frits Orskov (WHO E. coli and Klebsiella Reference Center, Statens Seruminstitut, Copenhagen, Denmark); its LD 50 in outbred ICR mice was~1 x 10 4 colony forming units (CFU). The P. aeruginosa strain (PA01) was a generous gift from Dr Gerald B. Pier (Boston, MA).
Mouse vaccination
Female outbred white mice (Cr1:CD-1[ICR]BR, 6-8-weekold; Charles River, Wilmington, MA, USA) were vaccinated with 1 µg of J5dLPS-OMP (by LPS weight) either i.n. or i.p. on weeks 0, 2, and 4. The i.n. administration of 25 µg CpG preceded i.n. vaccination with J5dLPS-OMP by 30-60 min to allow mucosal absorption. The i.n. administration of saline, CpG, or J5dLPS-OMP was given in a liquid volume of 5 µl into each nostril (10 µl total volume). The i.p. vaccinations were given as a single injection in a total volume of 200 µl. All dilutions were performed with sterile, endotoxinfree phosphate-buffered saline (PBS; Biosource International, Rockville, MD, USA). All experiments were approved by, and conducted in compliance with, the Institutional Animal Care and Use Committee of the University Of Maryland School Of Medicine.
Mouse pneumonia model
The day prior to challenge, frozen bacteria, stored in 10% casein stocks at -20°C, were streaked onto trypticase soy agar (TSA) plates and incubated 18 h at 37°C. On the day of challenge, single colony isolates were grown to mid-log phase in trypticase soy broth (TSB) at 37°C on an orbital shaker prior to washing and resuspending the cell pellet in sterile PBS to the desired challenge concentration. The actual inoculum of the challenge dose was confirmed by colony counts on TSA plates.
After at least 2 weeks from the last vaccination, lethal doses of a previously described K. pneumoniae O1:K2 14 were administered by a tongue-pull method to the lower respiratory tract (i.e. intratracheal route). Mice were anesthetized with isoflurane (Baxter; Deerfield, IL, USA) prior to the deposition of 50 µl of bacterial suspension to the posterior oropharynx. A successful challenge was confirmed by aspiration of the bacterial suspension and audible crackles. This method allowed the delivery of a consistent inoculum to each mouse. Each mouse was weighed daily until death (moribund mice were considered dead and euthanized) or until they ceased to lose weight over two consecutive days and demonstrated signs of improvement (e.g. increased activity). Those still surviving at 14 days were killed and bacterial organ counts were performed. The peak percentage weight loss for each mouse was calculated from the lowest post-challenge weight, prior to recovery or death, and the initial weight the day of the intratracheal challenge.
Serum and broncho-alveolar lavage fluid
In separate, prospectively-designated mice, serum and broncho-alveolar lavage fluid (BALF) was obtained 2 weeks after the third vaccination (day 42). Whole blood was obtained by cardiac puncture, after euthanasia. The collection of BALF was performed by cannulation of the trachea and gentle lavage of the lungs with a single round of 1 ml sterile PBS. Both serum and BALF were stored at 4°C until analysis was performed, usually within 1 week.
ELISA for anti-core glycolipid antibody
Serum and BALF samples were measured for anti-core glycolipid IgG and IgA antibody levels as previously described. 15 ELISA IgG antibody titers were calculated from a standard curve created from mouse monoclonal IgG antibody (Sigma) when comparing the optical density at 450 nm from the linear portion of the curve. ELISA IgA antibody titers were expressed as optical density units (ODU) calculated by multiplying the dilution factor by the optical density at 450 nm from the linear portion of the curve. Values were considered non-detectable (ND) if they were below the limits of detection for the assay (< 10 ng/ml). A vaccine 'responder' was defined as an antibody level that was ≥ 4 times that of the control mice.
Macrophage killing assay
Macrophages were cultured according to our previously described methods. 16 Primary peritoneal macrophages were obtained from naive ICR mice 4 days after i.p. inoculation of 3% Brewer Modified Thioglycollate Medium (Becton Dickinson; Cockeysville, MD, USA). Alveolar macrophages were obtained from matched naive ICR mice after four rounds of flushing the lungs with 1 ml PBS. In our hands, the recovered cells typically consisted of > 98% viability by Trypan Blue dye exclusion and > 95% macrophages as determined by immunofluorescence using the F4/80 macrophage marker. 17 Peritoneal or BAL fluid cell suspensions from mice were pooled and adjusted to 1 x 10 6 macrophages/ml in culture medium containing RPMI-1640 (Gibco-BRL; Frederick, MD, USA) with 5% fetal bovine serum (FBS; Atlanta Biologicals; Lawrenceville, GA, USA), and rested in polypropylene tubes (Elkay Products, Inc.; Shrewsbury, MA, USA) in 5% CO 2 at 37°C for 18 h.
Bacterial suspensions were freshly made from frozen stocks for each experiment as in the mouse pneumonia experiments. Bacteria, between 10 5 -10 6 CFU/ml, were opsonized by incubating at 4°C for 30 min on rotator with an equal volume of undiluted immune serum, immune BALF, control BALF, or sterile PBS (mock treatment). Macrophage-mediated killing by nitric oxide production was inhibited with 1 µM L-N 6 -(1-iminoethyl)lysine (L-NIL; Sigma). To determine macrophage-mediated killing at different time points, individual tubes containing infected macrophages were centrifuged at 380 g for 10 min after incubation for 1, 5, and 24 h. Cells were lysed with 1 ml of cold sterile distilled water at 37°C for 30 min, vortexed, and plated on TSA for the viable bacterial counts. The killing activity was measured by calculating the log difference in counts from time 0 to 1, 5 and 24 h.
Statistical analysis
Antibody ELISA results for both serum and BAL were expressed as arithmetic means with the standard error. Differences were analyzed by a non-parametric Kruskal-Wallis one-way analysis of variance for comparison of multiple groups or the Mann Whitney test for comparison of two groups. The survival functions of each vaccination group were expressed using Kaplan-Meier survival plots, and differences in survival were compared using the Logrank test. Macrophagemediated log reductions were analyzed by the Student's t-test. Results were considered significant with twosided P-values < 0.05. GraphPad Prism v.4.0 (San Diego, CA, USA) was used to perform these statistical calculations.
RESULTS
Following immunization, all mice demonstrated similar weight gain and had no overt adverse effects over 6 weeks (data not shown). Mice immunized with i.n. CpG alone had anti-core glycolipid antibody levels that were near the limits of detection of the assay. Mice immunized with PBS alone also had anti-core glycolipid antibody levels that were near the limits of detection (data not shown). All mice that received i.p. vaccination had robust systemic IgG responses, regardless of whether CpG was used. Mice vaccinated with J5dLPS-OMP plus a single dose of CpG via the i.p. route showed statistically higher systemic (serum) anti-core glycolipid IgG antibody titers than mice that were similarly vaccinated via the i.n. route (Fig. 1A) . When J5dLPS-OMP was administered i.n., alone or with CpG, mice achieved a mean serum IgG antibody level approximately 100-fold lower than that achieved by i.p. vaccine administration (without CpG). The addition of CpG resulted in a doubling of serum IgG antibody regardless of the route of administration. Therefore, a single dose of CpG in a multidose immunization regimen modestly increased the antibody response. The antibody responses (≥ 4-fold greater than control mice) of mice that received i.n.
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J5dLPS-OMP were not significantly different with the addition of CpG.
When examining BALF, i.p. vaccinated mice likewise had significantly higher IgG antibody levels than i.n. immunized mice (Fig. 1B) . Unlike the doubling observed in serum, the addition of CpG resulted in a 4-fold increase in BAL IgG antibody response when the vaccine was administered by either route. The i.p. route of administration resulted in 86-100% BALF IgG responders in comparison to 30% responders when delivered by the i.n. route of administration (P = 0.036, Fisher's Exact test).
Since IgA might be important as a first line of defense against mucosal infections, such as Gram-negative bacillary pneumonia, we measured the anti-core glycolipid IgA antibody levels in both the serum and BAL fluid samples after immunization by both routes of administration. Mice that received J5dLPS-OMP i.p. alone had little serum anti-core glycolipid IgA and the addition of CpG had did not increase the serum IgA antibody responses (Fig. 1C) . In comparison, mice that were given J5dLPS-OMP by the i.n. route of administration had modest serum IgA antibody responses; there was a trend toward higher IgA responses with the addition of CpG but this did not achieve statistical significance. When comparing serum IgA production based on those having a ≥ 4-fold response, no mouse responded to vaccination when immunized by the i.p. route, but 3 of 10 (P = 0.18, Fisher's Exact test) and 5 of 10 mice (P = 0.041, Fisher's Exact test) were vaccine responders when given i.n. J5dLPS-OMP alone or with the addition of CpG, respectively.
The level of BALF IgA for mice that were immunized i.p. with J5dLPS-OMP alone or with CpG was lower than mice that received vaccination by the i.n. route of administration (Fig. 1D) . Two of 7 mice that received i.p. vaccine alone had elevated IgA antibodies, and none of 7 mice that received i.p. vaccine plus CpG had elevated IgA antibodies. The ≥ 4-fold IgA response in mice vaccinated by the i.p. route was also lower than by the i.n. route of administration (P = 0.018, Fisher's Exact test). Thus, i.n. vaccination is superior to i.p. vaccination for the induction of IgA antibody responses.
Since a single dose of CpG was an effective immunoadjuvant for our vaccine, we speculated that concomitant administration of CpG with each of the three doses of 272 Chen, Kang, Bhattacharjee, Cross J5dLPS-OMP might increase the chance for each mouse to mount local and systemic antibodies. However, we found that two or three doses of CpG compared to a single dose did not significantly improve either serum or BAL IgG and IgA anti-core glycolipid responses when given by intramuscular, subcutaneous, or intraperitoneal routes of administration (data not shown).
A murine model of pneumonia, using the tongue-pull intratracheal route of administration, was used to evaluate whether i.n. vaccination with J5dLPS-OMP might be effective in protection against lethal Gram-negative bacillary pneumonia. We consistently observed 100% lethality with K. pneumoniae O1:K2 in ICR mice at doses ≥ 10 6 CFU, > 80% lethality at 10 5 CFU, 50% lethality at just under 10 4 CFU, and no lethality at 10 3 CFU. Therefore, the target dose for challenge experiments was~5 x 10 4 CFU, the linear portion of the lethality curve. Using this target dose in outbred mice resulted in progressive illness over 96 h with death typically occurring between 5-8 days' post-challenge. The K. pneumoniae O1:K2 isolate rapidly multiplied and disseminated in vivo; predictably 10 6 CFU/g of lung tissue and 100-1000 CFU/ml of blood were recoverable within the first 24 h after infection. At 96 h post-infection, mice had 10 7 CFU/g of lung tissue, 10 4 -10 5 CFU/ml of blood, and 10 5 -10 6 CFU/g of extrapulmonary tissue (i.e. liver and spleen).
In two separate challenge experiments, mice were immunized with three i.n. doses of J5dLPS-OMP plus CpG and compared to administration of PBS alone; all mice were challenged ≥ 2 weeks later. In pilot studies, mice vaccinated with CpG alone failed to demonstrate a survival benefit compared to saline (data not shown). Two weeks after the third vaccination, intratracheal challenges with K. pneumoniae O1:K2 at 5.8 x 10 4 CFU/mouse and 6.3 x 10 4 CFU/mouse were performed in the two experiments, respectively. Vaccinated mice showed improved survival when compared to control mice (P = 0.015, Logrank test; Fig. 2, top) . All surviving mice had complete clearance of bacterial infection as documented by the absence of culturable bacteria from the lungs and at distal sites at 10 days' post-challenge, except for a single well-appearing mouse from the vaccinated group which, at sacrifice, was found to have 9 x 10 6 CFU/ml in the lung, 2700 CFU/ml from spleen and no bacteria recovered from the liver. All mice that died had very high organ bacterial counts, > 10 8 CFU/g of tissue. The severity of pneumonia, as assessed by change in weight, trended toward less weight loss in the vaccinated mice (Fig. 2, bottom) . Note that in order to graph some censored data, we plotted the weights of mice at death; by day 8 post-challenge in the control group, only 3 surviving mice contribute to the curve. The peak percentage weight loss was calculated to compare the changes in weight, of each group, irrespective of whether individual mice lived or died. Mice immunized i.n. had 15.9% (95% CI, 10.1-21.7) peak percentage weight loss in comparison to 20.9% (95% CI, 16.1-25.5) in the control (PBS) group (P = not significant).
To assess whether i.n. vaccination might be superior to i.p., we immunized mice i.n. or i.p. with the same biweekly 3-dose regimen (vaccine + CpG). In three separate experiments with intratracheal challenge doses of K. pneumoniae O1:K2 at 7.6, 9.5, and 7.6 x 10 4 CFU/mouse, respectively, we observed improved survival in i.n. vaccinated mice and no survival in i.p. vaccinated mice (Fig. 3, top) when compared to control (PBS only) animals (P = 0.047, Logrank test). There was a delayed time to death among i.n. immunized mice (median survival of 11 days) in comparison to i.p. immunized (median survival of 7 days) and control animals (median survival of 9.5 days) The severity of pneumonia as measured by weight loss for i.n. immunized mice was less than i.p. vaccinated mice and control mice (Fig. 3,  bottom) . The peak percentage weight loss was 14.0% (95% CI, 10.1-17.9) in the i.n. group, 17.4% (95% CI, 12.7-22.1) in the i.p. group, and 24.7% (95% CI, 19.4-30.1) in the control group.
Given the survival benefit and reduced organ bacterial load among immunized mice, we hypothesized that the vaccine-induced antibodies enhanced the uptake and killing of bacteria by macrophages. In the macrophage killing assay, freshly isolated primary macrophages were allowed to phagocytose and kill bacteria that were preopsonized by heat-inactivated serum or BALF samples from control (i.n. CpG alone) and immunized mice. A single representative 'high titer' immune BALF sample (ELISA IgG = 200 ng/ml, IgA = 1.8 ODU), 'low titer' control BALF sample (ELISA IgG = 1 ng/ml, IgA = 0.7 ODU), and a 'high titer' immune serum sample (ELISA IgG of 230 µg/ml, no IgA) were selected for in vitro assays.
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The killing capacity of peritoneal macrophages on K. pneumoniae O1:K2 was examined at 24 h in three independent experiments with each experiment containing two replicates at each time point. (Fig. 4A) Immune BALF mediated greater killing in comparison to control BALF or untreated bacteria. Immune serum also mediated greater killing in comparison to control BALF and untreated bacteria and was statistically superior to that of immune BALF. Control BALF mediated a moderate amount of killing in comparison to untreated bacteria suggesting that additional non-immunoglobulin, noncomplement-mediated opsonization may have a role.
Since the vaccine was designed to elicit antibodies against conserved epitopes in Gram-negative bacteria, we tested the ability of these antibodies to enhance the killing of another heterologous Gram-negative bacillus, P. aeruginosa (PA01), in two separate experiments conducted in duplicate. Killing was assessed at 24 h with peritoneal macrophages infected with P. aeruginosa PAO1 that was pre-opsonized with the same serum and BALF samples as in the previous experiments (Fig. 4B) . Immune BALF and immune serum elicited significantly 274 Chen, Kang, Bhattacharjee, Cross 6 CFU). Data are expressed as mean from experiments with comparisons for significance calculated against the control BALF responses. NS, not significant; *P < 0.05; **P < 0.01; ***P < 0.005 by two-tailed Student's t-test.
higher killing than either control BALF or untreated bacteria. The opsonic activity of control BALF was not significantly different from that without treatment.
Since alveolar macrophages may be more relevant to the pneumonia model, we measured the killing function of alveolar macrophages on P. aeruginosa PAO1 in two separate experiments. The highest killing activity was found with immune BALF followed by intermediate killing with immune serum treated bacteria; however, neither treatment achieved statistical difference from control, BALF-treated bacteria (Fig. 4C) . The amount of bacterial killing mediated by control BALF was not different from that of untreated bacteria.
In order to dissect out the potential role of anti-core glycolipid antibody opsonization of bacteria on macrophage-mediated killing further, two separate experiments were conducted as in the previous experiments using immune serum that was diluted 1000-fold (with sterile PBS) in order to mimic the concentration of anti-core glycolipid IgG in the immune BALF. In separate reaction tubes, 1 µM L-NIL was added to macrophages infected with P. aeruginosa PAO1 pre-opsonized with immune serum in order to block nitric oxide production in macrophages, an effector of macrophage killing. At 5 h, immune serum and immune BALF demonstrated superior killing compared to control BALF and untreated bacteria. (Fig. 5) The 1000-fold dilution of the immune serum abolished killing, suggesting a potential role for anti-core glycolipid IgA as a mediator of killing. Killing was also abrogated when L-NIL was added to macrophages, suggesting that nitric oxide production is necessary for macrophage-mediated killing, independent of opsonins. On the whole, opsonization of these two heterologous Gram-negative bacteria with a single representative sample of immune serum and BALF appeared to mediate killing activity with peritoneal macrophages. This was also the trend when using alveolar macrophages.
DISCUSSION
We previously demonstrated protection with active and passive J5dLPS-OMP parenteral immunization against lethal homologous and heterologous monomicrobial and polymicrobial sepsis, 11, 12, 18 which was dependent on anticore glycolipid IgG antibodies. 15 The purpose of the present study was to: (i) assess whether the J5dLPS-OMP vaccine could elicit antibody responses in the respiratory tract by different routes of administration; (ii) determine if this core glycolipid vaccine can protect against lethal heterologous Gram-negative bacillary pneumonia; and (iii) identify a potential mechanism of action for antibodies elicited by the sepsis vaccine.
Few previous studies have examined the effect of i.n. immunization with glycolipid-based vaccines. Vaccines constructed from the detoxified LOS of non-typeable Haemophilus influenzae 19 and Moraxella catarrhalis 20 and non-detoxified LPS from Brucella melitensis 21, 22 and Shigella flexneri 2a and Shigella sonnei 23 have shown enhanced clearance or protection from pneumonia with homologous bacterial species. A live, attenuated Salmonella spp. expressing the O antigen portion of LPS from P. aeruginosa provided protection from heterologous strains of P. aeruginosa. 24 The current study shows protection from heterologous bacterial species.
Our results are consistent with the finding that i.n. delivery of glycolipid-based vaccines elicits both systemic and mucosal IgG and IgA, but parenteral delivery did not elicit a robust local IgA response. While there was no gross blood in the BALF which might indicate that systemic IgG from serum might have leaked inadvertently into the BAL samples during the lung washes, the possibility cannot be completely ruled out. If IgG is sufficient for protection from Gram-negative bacillary pneumonia, then parenteral vaccination may be adequate. However, if secretory IgA is an important line of defense against pathogens of the respiratory mucosal lining, then i.n. or alternative mucosal routes of administration might provide a more protective immune response.
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Fig. 5.
The bacterial counts at 5 h were assessed using freshly harvested primary peritoneal macrophages (10 6 ) and P. aeruginosa PA01 (MOI 1:1, 10 6 CFU) that had been pre-opsonized with the same immune serum, immune BALF, or control BALF as in the previous experiments. The immune serum was diluted 1000-fold in order to approximate the level of anti-core glycolipid IgG in the immune BALF. L-NIL (1 µM) was added to peritoneal macrophages that were infected with P. aeruginosa PAO1 pre-opsonized with immune serum to inhibit nitric oxide-mediated macrophage killing. Data are expressed as mean from two independent experiments each conducted in duplicate and comparisons were calculated against the control BAL response. NS, not significant; *P < 0.05; ***P < 0.005 by two-tailed Student's t-test.
Secretory IgA is generally accepted as helpful in the clearance of pathogens in the gut and nasal mucosa; this is done primarily by 'immune exclusion'. 25 However, secretory IgA does not fix complement nor induce phagocytosis in neutrophils or Kuppfer cells. 26 We are not aware of any studies that definitively demonstrate that secretory IgA grants any protection in the lower respiratory tract. In fact, the protective antibody of the lower respiratory tract is believed to be serum IgG. 25, 27 Furthermore, IgA deficiency is one of the most common primary immunoglobulin deficiencies yet most individuals are clinically asymptomatic. These data argue against a role for IgA as a protective factor in pneumonia.
Using our model of lethal heterologous Gram-negative bacillary pneumonia (by immunization with a detoxified E. coli LPS and challenge with a virulent K. pneumoniae isolate), we demonstrated a survival benefit with active i.n. immunization of J5dLPS-OMP with CpG compared to control animals, using an outbred strain of mice. Upon subsequent challenges with 33% higher doses of K. pneumoniae, i.n. vaccination provided superior protection to i.p. vaccination, suggesting IgA may be important for protection. We also showed significant differences in severity of pneumonia, as assessed by weight loss, between i.n. vaccinated and control mice. We used K. pneumoniae O1:K2 as our challenge organism because its high virulence. 28 When we challenged ICR mice by the intratracheal route of administration with P. aeruginosa isolates PAO1 and PA12.4.4, doses in excess of 10 8 CFU failed to achieve 50% lethality. Therefore, we did not proceed with in vivo vaccination protection studies with P. aeruginosa because the animal model would more likely reflect a model of endotoxemia rather than pneumonia.
In this current study, CpG was used as a potential immunostimulatory adjuvant for the J5dLPS-OMP vaccine. The specific dinucleotide motifs in these chemically synthesized sequences are known to stimulate antigen presenting cells via Toll-like receptor 9 and are optimized for each animal species. These CpG ODNs have been shown to enhance significantly systemic and mucosal immune responses to protein vaccines, such as purified hepatitis B surface antigen, when given mucosally. 29 On the other hand, CpG ODN can activate nonspecific innate immune responses resulting in protection from lethal bacterial challenges, yet these systemic responses wane rapidly [30] [31] [32] and persist less than 10 days when administered via the respiratory tract. 33, 34 The improved survival from pneumonia in mice that received vaccine and CpG i.n. are not likely the result of non-specific responses from CpG since our mice were administered the last dose of CpG at least 2 weeks prior to challenge.
Protection is correlated with anti-core glycolipid antibody. Vaccination followed by lethal infection with P. aeruginosa and K. pneumoniae in the neutropenic rat model of sepsis and the murine cecal ligation and puncture (CLP) model of lethal polymicrobial sepsis was associated with high levels of anti-core glycolipid IgG, increased survival, lower organ bacterial counts (liver and spleen), lower TNF-α, and lower endotoxin levels when compared to control animals. 12, 15, 18 Furthermore, within 24-48 h of infection, there was a significant decline in anti-core glycolipid IgG without a significant decline in OMP-specific IgG which argues against the decline in anti-core glycolipid antibody as due to a generalized hypermetabolic state. The reduction in bacterial loading and increased protection afforded by anti-core glycolipid antibody has been extended to another Gramnegative pathogen, Francisella tularensis, in a murine model of lethal pneumonia (abstract presented at 2008 Tularemia Workshop; manuscript in preparation).
Building on these observations, in the current study we show a correlation with clearance of infection and protection from lethal challenge in vivo and enhanced killing of both K. pneumoniae and P. aeruginosa with primary macrophages in vitro which seems to be based on the antibodies elicited by the vaccine. An alternative explanation for the modest, but significantly enhanced, in vitro bactericidal activity is the non-specific, nonmacrophage enhancement of antibacterial lung defenses. 35 The increased colony counts with addition of L-NIL, which blocks nitric oxide production and is a critical antibacterial effector in phagocytes, suggests that macrophage-mediated killing was probably responsible for the differences in viable bacterial counts in our assay. Since protection from an infection can be achieved against a number of mucosal pathogens with the elicitation of high levels of serum IgG, 36, 37 the magnitude of BAL anti-core glycolipid IgG elicited by parenteral administration of the core glycolipid vaccine might obscure the contribution of local anti-core glycolipid IgA antibodies produced by i.n. vaccination. When anticore glycolipid IgG of immune serum was diluted to a level approximately equal to that of the immune BALF, enhanced killing was observed with the BALF only. Since the critical difference between diluted immune serum and immune BALF is the presence of anti-core glycolipid IgA (the IgG is approximately the same), IgA may be important for protection. It is not clear, however, if and how IgA might promote phagocytosis. The reduction in killing with the dilution of serum 1000-fold does not rule out the possibility of non-Ig, non-complement opsonins as the reason for enhanced in vitro killing.
Resident alveolar macrophages differ from other macrophages, such as peritoneal macrophages, in that they are capable of ingesting large quantities of foreign particulate while remaining relatively quiescent and avoiding the potential for collateral tissue damage by the elaboration of pro-inflammatory responses in the lung. 38 However, despite those differences, we show that alveolar macrophages were similar to peritoneal macrophages in their ability to kill opsonized PAO1 in vitro.
CONCLUSIONS
The ability of this vaccine to protect against lethal heterologous Gram-negative bacillary pneumonia either by mucosal IgA and/or systemic and mucosal IgG following intranasal or parenteral routes of administration warrants further investigation.
